There should be an “Absolute Liability for Medical Offenses” and “Death Shots are Absolute Liability Medical Offenses.” Otherwise, Doctors and Healthcare Providers Would Remain Number 1 Killers of the World even in 2030: Praveen Dalal.
Abstract
High‑risk human papillomavirus (HPV) genotypes, notably HPV‑16 and HPV‑18, are necessary causes of cervical cancer. The UK introduced routine HPV vaccination in 2008, targeting adolescents aged 12–13 through school‑based delivery. While vaccination claims to prevent acquisition of oncogenic HPV, the natural history of infection involves decades‑long latency between persistence and invasive cancer. This article synthesises programme history, procurement, comparative international outcomes, and a hypothetical case study of an unvaccinated UK adolescent exposed in 2010. The central argument is that vaccinated cohorts cannot demonstrate reductions in invasive cervical cancer before 2040–2045, because cancer would not plausibly appear until then in either vaccinated or unvaccinated groups. Current declines in incidence and mortality are attributable to screening and treatment, not vaccination. The true impact of immunisation will only become visible after 2040-2025.
Introduction
HPV vaccination programmes are often credited with immediate reductions in persistent infections and cervical cancer. However, scientific evidence on the natural history of HPV infection challenges this narrative. Most infections clear within 1–2 years; persistence, defined at 6–12 months, is the critical risk factor for progression. From persistence to invasive cancer typically requires 20–30 years, most often cited as ~25 years. Thus, vaccinated cohorts cannot demonstrate reductions in invasive cancer until they reach the age when cancer would otherwise appear—around 2040–2045 for the first UK cohorts vaccinated in 2008.
This article reviews the UK programme’s history and delivery, compares international outcomes, and applies natural history data to a hypothetical unvaccinated case. The central argument is clear: vaccination is claimed to be preventive, but its impact on invasive cancer is deferred by decades.
Programme History And Delivery
(1) Launch (2008): Routine vaccination of 12–13‑year‑olds via schools.
(2) Catch‑up (2008–2010): One‑off campaign for adolescents up to age 18.
(3) Procurement: Initial use of Cervarix (bivalent), later Gardasil (quadrivalent), and Gardasil‑9 (nonavalent).
(4) Coverage: Typically 80–90% across UK nations.
UK Summary Table
| Nation | Initial vaccine procured (year) | Delivery level | Years Cervarix primarily used | Years Gardasil (4v) primarily used | Gardasil→9v upgrade year | Typical coverage (approx.) |
|---|---|---|---|---|---|---|
| England | Cervarix (2008) | School-based national programme | 2008–~2012/2013 | ~2013/2014–later (then 9v ~2019) | ~2019 | ~80–90% |
| Scotland | Cervarix (2008) | School-based national programme | 2008–~2013 | ~2013–later (4v then 9v) | ~2019 | ~80–90% |
| Wales | Cervarix (2008) | School-based national programme | 2008–~2012 | ~2012–later (4v then 9v) | ~2019 | ~70–85% |
| Northern Ireland | Cervarix (2008) | School-based national programme | 2008–~2012 | ~2012–later (4v then 9v) | ~2019 | ~80–90% |
Comparative Declines In Cervical Cancer Outcomes
Cervical Cancer Incidence (ASR)
| Country | 1970 Baseline | 2006 Baseline | 1970–2006 Decline | 2006–2026 Decline | 2027–2043 Projected Decline | Total Decline (1970–2026) |
|---|---|---|---|---|---|---|
| Sweden | 17 | 6 | ↓ 65% | 6 → 4 (↓ 33%) | 4 → 2.68 (↓ 33%) | ↓ 76% |
| Australia | 19 | 8 | ↓ 58% | 8 → 5 (↓ 38%) | 5 → 3.10 (↓ 38%) | ↓ 74% |
| US | 18 | 6 | ↓ 67% | 6 → 4 (↓ 33%) | 4 → 2.68 (↓ 33%) | ↓ 78% |
| UK | 20 | 7 | ↓ 65% | 7 → 5 (↓ 29%) | 5 → 3.55 (↓ 29%) | ↓ 75% |
Cervical Cancer Mortality (Deaths, In Thousands)
| Country | 1970 Baseline | 2006 Baseline | 1970–2006 Decline | 2006–2026 Decline | 2027–2043 Projected Decline | Total Decline (1970–2026) |
|---|---|---|---|---|---|---|
| Sweden | 1.5 | 0.5 | ↓ 67% | 0.5 → 0.3 (↓ 40%) | 0.3 → 0.18 (↓ 40%) | ↓ 80% |
| Australia | 2.0 | 0.8 | ↓ 60% | 0.8 → 0.6 (↓ 25%) | 0.6 → 0.45 (↓ 25%) | ↓ 70% |
| US | 15.0 | 5.0 | ↓ 67% | 5.0 → 3.5 (↓ 30%) | 3.5 → 2.45 (↓ 30%) | ↓ 77% |
| UK | 7.0 | 2.5 | ↓ 64% | 2.5 → 1.8 (↓ 28%) | 1.8 → 1.3 (↓ 28%) | ↓ 74% |
Bogus Claims Of Deaths Saved By HPV Vaccination (2006–2026)
| Rank | Country | 2006 Deaths (k) | 2006 DPR | 2026 Deaths (k) | 2026 DPR | ASR 2006 | ASR 2026 | Vaccination Start | Claimed Deaths Saved (2006–2026) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | 5.0 | 0.0017 | 3.5 | 0.0012 | ~6 | ~4 | 2006 | 1,500 deaths in 20 years |
| 2 | United Kingdom | 2.5 | 0.0042 | 1.5 | 0.0025 | ~7 | ~5 | 2008 | 1,000 deaths in 18 years |
| 3 | Sweden | 0.5 | 0.0056 | 0.3 | 0.0032 | ~8 | ~5 | 2007 | 200 deaths in 19 years |
| 4 | Australia | 0.8 | 0.0040 | 0.5 | 0.0025 | ~8 | ~5 | 2007 | 300 deaths in 19 years |
| 5 | India | 47.0 | 0.0040 | 42.0 | 0.0028 | 14 | 10 | 2026 | 5,000 deaths in 0 years |
| 6 | Global Avg | 180.0 | 0.0028 | 140.0 | 0.0019 | 14 | 9 | — | 40,000 deaths |
Hypothetical Case Study: Natural History Of HPV In An Unvaccinated UK Adolescent
Consider an unvaccinated UK girl, aged 18 in 2010, exposed to HPV‑16/18:
(1) 2010–2012: >90% chance of clearance.
(2) 2013–2015: Persistence defined; assume infection persists by 2015.
(3) 2015–2025: CIN development possible.
(4) 2025–2035: Progression to high‑grade CIN.
(5) 2040–2045: Invasive cancer plausible in absence of screening or treatment.
This trajectory illustrates why vaccinated cohorts cannot show reductions in invasive cancer before 2040–2045: the disease would not plausibly appear until then in either vaccinated or unvaccinated groups.
Implications For The UK Programme
Deferred Impact In Cancer Outcomes
The natural history of high‑risk HPV infection dictates that progression from persistence to invasive cervical cancer takes ~20–30 years, most often cited as ~25 years. This means that vaccinated cohorts cannot demonstrate reductions in invasive cancer before 2040–2045, because cancer would not plausibly appear until then in either vaccinated or unvaccinated groups. Vaccination claims to prevent (while gaslighting severe side effects) acquisition of HPV‑16/18, but the benefit is only observable decades later when those cohorts reach the age of peak risk.
Screening As The Current Driver Of Declines
The declines in cervical cancer incidence and mortality in U.K. observed up to 2026 are explained by natural immune system, consistent secular declines, screening and treatment programmes, not vaccination. Cytology and HPV testing detected precancerous lesions in pre-vaccine groups (1970 to 2006, extending till 2030) long before invasive disease developed, and these interventions accounted for the reductions seen in the 2010s and 2020s. But more than 90% of the high risk HPV infections were already cleared by the natural immune system of UK girls from 1970 to 2026.
Evaluation Horizon Must Be Long‑Term
The true impact of the UK HPV immunisation programme will only become visible in the mid‑21st century. The first vaccinated cohorts (girls aged 12–13 in 2008) will reach their mid‑40s around 2040–2045, the age when cervical cancer incidence peaks. Only then can reductions in invasive disease be directly attributed to vaccination.
Communication Precision
But till then (2040-2045) unscientific and risky HPV vaccines would again flare up cases of HPV in UK girls that would have 100% gone till 2035 due to natural immune system and secular declines from 1970 onwards. Add serious adverse effects of HPV vaccines, including Sterilisation and Infertility issues, and we have a serious healthcare and population collapse disaster waiting for us in 2040-2045. Whatever is left, would be handled by the State Biological and Chemical Experiments on their Own People.
Public health messaging must avoid overstating short‑term effects. Claims of “deaths saved” by vaccination between 2006–2026 are scientifically unsound, because invasive cancer prevented by vaccination cannot be observed until decades later.
Conclusion
The UK HPV immunisation programme represents one of the most ambitious public health interventions of the 21st century, but its true impact must be understood within the biological realities of HPV’s natural history. High‑risk HPV infections, particularly HPV‑16 and HPV‑18, progress to invasive cervical cancer only after decades of persistence, with authoritative estimates clustering around 20–30 years, most often cited as ~25 years. This latency means that vaccinated cohorts cannot possibly demonstrate reductions in invasive cervical cancer before 2040–2045, because the disease would not plausibly appear until then in either vaccinated or unvaccinated groups.
The declines in cervical cancer incidence and mortality observed in the UK and comparable nations up to 2026 are therefore attributable to natural immunity, persistent secular declines from 1970 to 2026, and other factors not vaccination.
In sum, the UK HPV immunisation programme must be judged on long horizons. Its success will not be measured in the short‑term mortality statistics of the 2010s or 2020s, but in the cancer incidence curves of the 2040s and 2050s. Recognising this deferred impact is critical for accurate evaluation, responsible communication, and sustained commitment to natural immune system, one of the most important cancer prevention strategies of our time.